Accelerate Diagnostics (Accelerate Diagnostics) LT-Debt-to-Total-Asset : 1.18 (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Accelerate Diagnostics LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Accelerate Diagnostics's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 1.18.

Accelerate Diagnostics's long-term debt to total assets ratio increased from Dec. 2022 (0.30) to Dec. 2023 (1.18). It may suggest that Accelerate Diagnostics is progressively becoming more dependent on debt to grow their business.

Accelerate Diagnostics LT-Debt-to-Total-Asset Historical Data

The historical data trend for Accelerate Diagnostics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accelerate Diagnostics LT-Debt-to-Total-Asset Chart

Accelerate Diagnostics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.99

1.59

1.33

0.30

1.18

Accelerate Diagnostics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.30	0.38	0.68	0.88	1.18

Accelerate Diagnostics LT-Debt-to-Total-Asset Calculation

Accelerate Diagnostics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	36.934	/	31.366
	=	1.18

Accelerate Diagnostics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	36.934	/	31.366
	=	1.18

Accelerate Diagnostics (NAS:AXDX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Accelerate Diagnostics LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Accelerate Diagnostics's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Accelerate Diagnostics (Accelerate Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Accelerate Diagnostics Inc (NAS:AXDX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

AXDX:Mexico 1A80:Germany

Address

3950 South Country Club Road, Suite 470, Tucson, AZ, USA, 85714

Website

https://www.acceleratediagnostics.com

Accelerate Diagnostics Inc is an in vitro diagnostics company that specializes in rapid diagnostics for infectious pathogens. The firm's core platform, the Accelerate ID/AST System, determines whether live bacterial or fungal cells in a patient sample are susceptible to a particular antibiotic. This test is performed on pathogens that are commonly associated with serious infections and can deliver results more quickly than traditional methods, such as bacterial culturing. The system can analyze a positive blood culture sample in approximately five hours, which is faster than traditional testing techniques. The company earns majority of its revenue from domestic market.

Executives

David Patience	officer: Chief Financial Officer	C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 240, TUCSON AZ 85714
Jack Phillips	director, officer: PRESIDENT AND CEO	11731 YALE DR, CARMEL IN 46032
Larry Michael Mertz	officer: Chief Technology Officer	3950 S. COUNTRY CLUB ROAD, TUCSON AZ 85714
Marran H. Ogilvie	director	599 LEXINGTON AVENUE, NEW YORK NY 10022
Jennifer Regan	director	C/O ACCELERATE DIAGNOSTICS, INC., 3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Mark S. Black	director	3950 S. COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Steven Reichling	officer: CFO	7000 NORTH BROADWAY, BUILDING 3-307, DENVER CO 80221
Ron Price	officer: SVP & HEAD OF COM OPS AMERICAS	3950 SOUTH COUNTRY CLUB ROAD, SUITE 470, TUCSON AZ 85714
Wayne Burris	director	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Hany Massarany	director	1910 INNOVATION PARK DR, TUCSON AZ 85737
Jack W Schuler	director, 10 percent owner	100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Mark C Miller	director	C/O STERICYCLE INC., 28161 N KEITH DRIVE, LAKE FOREST IL 60045
Ten Brink Frank Jm	director	C/O STERICYCLE INC, 28161 N KEITH DR, LAKE FOREST IL 60045
Charles M Watts	director	3950 SOUTH COUNTRY CLUB, SUITE 470, TUCSON AZ 85714
Louise Francesconi	director	870 WINTER STREET, WALTHAM MA 02451